bigger Created with Sketch.

News & Events

News & Events

To sign up for news alerts, please e-mail info@homologymedicines.com

For media inquiries, please email cmayfield@homologymedicines.com

News
& Events

Current News & Events | Archived News & Events
05/13/2021
Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting ​
05/06/2021
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights​
05/03/2021
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting​
04/28/2021
Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model​
04/14/2021
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting​
04/12/2021
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer ​
04/07/2021
Homology Medicines Announces Pricing of Public Offering of Common Stock​
04/06/2021
Homology Medicines Announces Proposed Public Offering of Common Stock​
03/11/2021
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights​
03/01/2021
Rare Disease Day 2021: Recognizing the Superheroes Among Us​
03/01/2021
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform​
02/25/2021
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences​
02/08/2021
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome​
01/26/2021
Homology Medicines Announces Publication in Life Science Leader ​
01/06/2021
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II) ​
11/09/2020
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights​
11/09/2020
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.​
11/06/2020
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU​
11/05/2020
Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU ​
10/22/2020
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome ​
09/18/2020
Homology Medicines to Participate in Upcoming Conferences​
08/10/2020
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update ​
07/21/2020
Homology Medicines Appoints Jeff Poulton to the Board of Directors​
05/26/2020
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program​